News Sentiment

YDES sentiment intelligence

YD Bio Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 21 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.23 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

80/100 classification confidence.

Company focus 12

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+17.4% over one week, -31.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Enterprise value to revenue forward of YD Bio Limited – NASDAQ:YDES

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 80/100 classification
One-week reaction 17.4% Price confirming higher
Trend fit Trend inactive -31.8% over four weeks
Fair value -77.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 16
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 12
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
Stock Titan 6
TradingView 3
simplywall.st 2
Investing.com Canada 1
Kalkine 1
Finviz 1
Intellectia AI 1

Event Lens

What the news is about

Classified themes
Earnings 13
Market update 7
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-21 of 21
Investing.com Canada Direct company coverage

YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania By Investing.com

YD Bio's affiliate, EG BioMed US Inc., has secured clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its operational reach to 46 U.S. states, Washington D.C., and Guam. The expansion comes as YD Bio's stock (NASDAQ:YDES) has seen a significant decline, trad

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:11
Source
Investing.com Canada
Stock Titan Direct company coverage

YD Bio expands cancer-testing lab access to 46 states

YD Bio (Nasdaq:YDES) announced that its affiliate, EG BioMed US, has secured out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited Bothell, Washington lab. This expansion grows its authorized operations to 46 U.S. states

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 11:40
Source
Stock Titan
Stock Titan Direct company coverage

RSU grant and exercise for YD Bio (YDES) director Chang Kochi

YD Bio Ltd director Chang Kochi reported exercising 5,749 Restricted Share Units (RSUs) into ordinary shares and simultaneously receiving a new grant of 5,749 RSUs on June 30, 2026. After these transactions, Kochi directly holds 7,830 ordinary shares. The new RSU grant has a targ

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:33
Source
Stock Titan
Stock Titan Direct company coverage

RSU grant and exercise update for YD Bio (YDES) director Lu

YD Bio Ltd. director Lu Shao-Ta reported exercising 5,749 Restricted Share Units (RSUs) into ordinary shares and receiving a new grant of 5,749 RSUs. These transactions update his direct holdings to 7,830 ordinary shares and indirect holdings (through his spouse) to 51,151 ordina

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:33
Source
Stock Titan
Finviz Direct company coverage

YDES - YD Bio Ltd Stock Price and Quote

This article provides detailed financial information and recent news for YD Bio Ltd (YDES). It includes stock performance, key financial metrics, insider and institutional ownership, and a list of significant corporate announcements such as financial results, strategic partnershi

Tone
Neutral 50/100
Event
Earnings
Published
02 Jun 2026 08:10
Source
Finviz
Stock Titan Direct company coverage

[EFFECT] YD Bio Ltd SEC Filing

This article reports on YD Bio Ltd.'s SEC Filing, specifically a Notice of Effectiveness for an EFFECT form submitted on May 29, 2026. The filing's impact and sentiment are noted as "Neutral." The article also provides an overview of YD Bio's stock (NASDAQ: YDES), its market cap,

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

Revenue climbs but YD Bio (Nasdaq: YDES) posts $8.3M 2025 net loss

YD Bio (Nasdaq: YDES) reported a significant increase in net loss to $8.3 million in 2025, up from $1.4 million in 2024, despite a 17% rise in net revenue to $596,817. The widening loss was primarily driven by a surge in operating expenses, including higher professional fees, R&D

Tone
Negative 31/100
Event
Earnings
Published
03 May 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

After a $13.9M equity raise, YD Bio enters 2026 with $6M cash

YD Bio (Nasdaq: YDES) reported full-year 2025 results with net revenue increasing by 17% to $596.8K, while net loss widened significantly to $8.31M from $1.41M in 2024, primarily due to increased operating expenses including R&D and staff costs. Despite the wider loss, the compan

Tone
Negative 33/100
Event
Earnings
Published
01 May 2026 07:09
Source
Stock Titan
Intellectia AI Direct company coverage

YDES Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for YD Bio Ltd (YDES). As of April 2, 2026, the overall technical consensus for YDES is a "Sell," with a combination of moving averages and oscillators pointing to this sentiment. Key indicators like MACD and cer

Tone
Negative 37/100
Event
Guidance
Published
02 Apr 2026 07:10
Source
Intellectia AI